Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...
Raising 2025 NERLYNX® revenue and net income estimates
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, Nov. 6, 2025, following the release of its third quarter 2025...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted...
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that on September 2, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 5, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...